From CNBC: 2024-03-26 16:27:20

Viking Therapeutics stock soared over 15% after positive phase one results for their weight loss pill, entering next development stage this year. Potential competitor in $100 billion weight loss drug market against Novo Nordisk and Eli Lilly. Shares up 345% this year. Patients lost up to 5.3% of weight on average.

Phase one trial followed 40+ obese patients for one month. Those who took the weight loss pill lost up to 5.3% more weight than placebo group. Up to 57% of patients lost 5% body weight with the pill. Minimal side effects reported, including no vomiting with the pill.

Viking plans phase two trial for weight loss pill. CEO noted sustained weight loss even after missing doses. Trial suggests pill is safe and tolerable. Analysts compare Viking’s pill to Eli Lilly’s Zepbound, both containing gut hormones GLP-1 and GIP. Novo Nordisk’s Wegovy only targets GLP-1.



Read more at CNBC: Viking Therapeutics weight loss pill shows positive study results